Replies to post #271390 on Innovation Pharmaceuticals Inc (IPIX)

[farrell90]

Actually Kevetin was awarded Orphan drug status based on substantial preclinical study of Kevetrin for Pancreatic Cancer.

"Currently there are no Kevetrin data (that I know of) for pancreatic cancer."

The reports below outlines the data which lead to Kevetrin's Orphan drug approval.

"In vivo efficacy of Kevetrin in the pancreatic MIA PaCa-2 xenograft model showed that tumor volumes were significantly reduced by 82% during 3 weeks of dosing at 200mg/kg. In a separate experiment when Kevetrin alone was dosed at 150mg/kg the tumor volume was reduced by 54%. The combination of Kevetrin and irinotecan further reduced tumor volumes by 88% showing synergistic activity.

https://www.biospace.com/article/releases/cellceutix-releases-data-used-in-receiving-fda-orphan-drug-designation-of-kevetrin-for-pancreatic-cancer-/

http://www.ipharminc.com/press-release/2016/11/17/cellceutixs-kevetrin-slows-pancreatic-cancer-tumor-growth-by-94-protocol-towards-clinical-trial-nearing

IPIX has postponed FDA trials while it awaits development of an oral form of Kevetrin.

https://www.pm360online.com/cellceutix-reports-advances-in-developing-kevetrin-as-an-oral-ovarian-cancer-treatment-company-seeks-to-develop-worlds-first-p53-modulating-oral-cancer-drug/

A patient with Pancreatic cancer was treated in the stage 1 trial:

"A Phase 1 clinical study was conducted with Kevetrin administered once weekly for 3 weeks with an off-week between cycles. Only one patient with pancreatic cancer was enrolled in the trial. The patient, who was diagnosed with pancreatic cancer received four full cycles of Kevetrin. Tumor measurements showed stable disease for more than three months."

https://www.biospace.com/article/releases/cellceutix-releases-data-used-in-receiving-fda-orphan-drug-designation-of-kevetrin-for-pancreatic-cancer-/

IMO it is doubtful an institution,clinic or oncologist would assume the responsibility of recommending Kevetrin, at its current stage of development, for a Supreme Court Justice with terminal Pancreatic Cancer.

GLTA Farrell